Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

losoxantrone

Known as: 7-hydroxy-2(2-((2-hydroxyethyl) amino) ethyl)5-(2-((2-hydroxyethyl)amino)ethyl)amino anthra(1,9-cd)pyrazole-6(2H)-one 
An anthrapyrazole-based antineoplastic antibiotic. Losoxantrone intercalates into DNA, induces single- and double-stranded DNA breaks and inhibits… Expand
National Institutes of Health

Related topics

Related topics

10 relations

Broader (3)

AnthraquinonesAntineoplastic AgentsPyrazolones

Narrower (3)

BiantrazoleCI 941DuP 941
Losoxantrone HydrochlorideNSC 357885anthrapyrazolonecyclophosphamide/losoxantrone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
A Structure-Based 3D-QSAR Study of Anthrapyrazole Analogues of the Anticancer Agents Losoxantrone and Piroxantrone
A series of 13 anthrapyrazole compounds that are analogues of piroxantrone and losoxantrone were synthesized, and their cell… Expand
2002
2002
The oxidative biotransformation of losoxantrone (CI-941).
The oxidative biotransformation of the anticancer drug 7-hydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-[(2-hydroxyethyl)amino… Expand
  • figure 2
  • figure 3
  • figure 4
  • figure 5
  • figure 6
2001
2001
DNA-interactive anticancer aza-anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action.
The physicochemical and DNA-binding properties of anticancer 9-aza-anthrapyrazoles (9-aza-APs) were investigated and compared… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 2
2000
2000
A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer.
Our purpose in this study was to determine the efficacy and toxicity of losoxantrone (DuP-941), an anthrapyrazole, in patients… Expand
  • table 2
  • table 1
  • table 3
1999
1999
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
A Phase I and pharmacological study was performed to evaluate the feasibility, maximum tolerated dose (MTD), dose-limiting… Expand
Review
1999
Review
1999
Paclitaxel and anthracycline combination chemotherapy for metastatic breast cancer.
  • P. Kaufman
  • Seminars in oncology
  • 1999
    • Corpus ID: 40309823
Numerous clinical trials have demonstrated that the combination of paclitaxel and doxorubicin is extremely active in metastatic… Expand
1998
1998
Comparison of the chronic toxicity of piroxantrone, losoxantrone and doxorubicin in spontaneously hypertensive rats.
Comparisons were made of the toxic effects produced in the heart, kidney and small intestine of spontaneously hypertensive rats… Expand
1996
1996
Validation of cleaning procedures for highly potent drugs. I. Losoxantrone.
The validation of a procedure designed to clean glass and stainless steel surfaces after exposure to the experimental anticancer… Expand
Highly Cited
1994
Highly Cited
1994
Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen.
BACKGROUND The cumulative cardiotoxicity of anthracyclines is thought to result from the generation of free radicals. New DNA… Expand
Review
1994
Review
1994
New chemotherapeutic agents for breast cancer
The drug discovery programs of the National Cancer Institute and the pharmaceutical industry recently have provided oncologists… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE